Author Correction: Immunogenicity and efficacy of CNA25 as a potential whole-cell vaccine against systemic candidiasis
Satya Ranjan Sahu, Abinash Dutta, Doureradjou Peroumal, Premlata Kumari, Bhabasha Gyanadeep Utakalaja, Shraddheya Kumar Patel, Narottam Acharya
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
Topicsvaccines and immunoinformatics approaches · Bacterial Infections and Vaccines · Antifungal resistance and susceptibility
Correction to: EMBO Molecular Medicine (2024) 16:1254–1283. 10.1038/s44321-024-00080-8 | Published online 23 May 2024
Figure 9 is withdrawn and replaced.
Figure 9 Original.
Figure 9 Corrected.
Table EV1 is withdrawn and replaced.
Original published Table EV1 Table EV1Survival rate of mice challenged with Candida strains.StrainsMean death time (days)C. albicans and non-albicans sp. virulence C. albicans6 C. parapsilosis20 C. tropicalis9 C. glabrata9 Cross-species protection (1°-IV) Saline-(2°) C. albicans7 (1°-IV) CNA25 HK-(2°) C. albicans5 (1°-IV) CNA25-(2°) C. tropicalis19 Differential mode of immunization (1°-Oral) CNA25-(2°) WT22 (1°-Oral) Saline-(2°) WT7 (1°-IP) Saline-(2°) WT5 (1°-IP) CNA25-(2°) WT10 (1°-SC) Saline-(2°) WT5 (1°-SC) CNA25-(2°) WT7 Dectin-1 and TLR2 depletion 1°Saline-2°WT6 1°CNA25-(Anti-Dectin-1)-2°WT9 1°CNA25-(Anti-TLR2)-2°WTundefined CD4 and CD8 depletion 1°Saline-2°WT6 1°CNA25-(Anti-CD4)-2°WT7 1°CNA25-(Anti CD8)-2°WT10 IFNγ, IL17 and TNFα depletion 1°Saline-2°WT6 1°CNA25-(Anit-IFNγ)-2°WT6 1°CNA25-(Anti-IL17)-2°WT6 1°CNA25-(Anti-TNFα)-2°WT8 SCID mice 1°WT (n = 3)2 1°CNA25-2°WT (n = 6)5 Cyclophosphamide treatment (CPM+)-1°WT (5 × 10^5^CFU)2 (CPM+)-1°CNA25 (5 × 10^5^CFU)3 (CPM+)-1°WT (1 × 10^4^CFU)6
Corrected published Table EV1 Table EV1Survival rate of mice challenged with Candida strains.StrainsMedian death time (days)C. albicans and non-albicans sp. virulence C. albicans6 C. parapsilosis20 C. tropicalis9 C. glabrata9 Cross-species protection (1°-IV) Saline-(2°) C. albicans7 (1°-IV) CNA25 HK-(2°) C. albicans5 (1°-IV) CNA25-(2°) C. tropicalis19 Differential mode of immunization (1°-Oral) CNA25-(2°) WT22 (1°-Oral) Saline-(2°) WT7 (1°-IP) Saline-(2°) WT5 (1°-IP) CNA25-(2°) WT10 (1°-SC) Saline-(2°) WT5 (1°-SC) CNA25-(2°) WT7 Dectin-1 and TLR2 depletion 1°Saline-2°WT6 1°CNA25-(Anti-Dectin-1)-2°WT9 1°CNA25-(Anti-TLR2)-2°WTundefined CD4 and CD8 depletion 1°Saline-2°WT6 1°CNA25-(Anti-CD4)-2°WT7 1°CNA25-(Anti CD8)-2°WT10 IFNγ, IL17 and TNFα depletion 1°Saline-2°WT6 1°CNA25-(Anit-IFNγ)-2°WT6 1°CNA25-(Anti-IL17)-2°WT6 1°CNA25-(Anti-TNFα)-2°WT8 SCID mice 1°WT (n = 3)2 1°CNA25-2°WT (n = 6)5 Cyclophosphamide treatment (CPM+)-1°WT (5 × 10^5^CFU)2 (CPM+)-1°CNA25 (5 × 10^5^CFU)3 (CPM+)-1°WT (1 × 10^4^CFU)6
The authors contacted the journal after identifying errors in Figure 9 and Table EV1 of the published article. The authors provided the journal with the corrected figure and table, and after review, the journal withdraws and replaces Figure 9 and Table EV1.
Author statement:
In Figures 9A and 9B, we found that the graphs were inadvertently duplicated with different graph legends. However, the published source data and their descriptions in the results section remain correct. The corrected Figure 9, now provided, maintains all original conclusions.
Additionally, a typographical correction in Table EV1, correcting ‘mean death time’ to ‘median death time,’ does not affect the study’s findings.
All authors agree to this correction and apologise for any inconvenience caused.